Evidence map›Paper›PMID 28929201›Full record

SynthesisInternational urogynecology journal2018

Pelvic floor disorders in women with gynecologic malignancies: a systematic review.

Aparna S Ramaseshan, Jessica Felton, Dana Roque, Gautam Rao, Andrea G Shipper, Tatiana V D Sanses

2 registry-linked trialsOpen access · greenAbstract readSystematic Review
In one paragraph

Synthesis in International urogynecology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 49 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 5 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04515888 completednot on this mapstarted 2020, after this paper: background citation

Evaluation of the Prevalence of Pelvic Static Disorders in Women Treated for Localized Breast Cancer During Adjuvant Hormone Therapy.

TypeobservationalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2020 to 2021Enrolled246ConditionsBreast CancerArmsPFDI-20 / PFIQ-7 questionnaires
NCT06786091 nacompletednot on this mapstarted 2025, after this paper: background citation

Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment

TypeinterventionalSponsorSt. Olavs HospitalRan2025 to 2026Enrolled25ConditionsPelvic Floor Disorder, Female Pelvic Floor Dysfunction, Female Sexual Dysfunction, Female Urinary IncontinenceArmsPelvic floor muscle training rehabilitation
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 5 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. An allied health rehabilitation program for patients following surgery for abdomino-pelvic cancer: a feasibility and pilot clinical study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Trial
  8. Trial
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Aparna S RamaseshanDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD, USA. rama.aparna@gmail.com.ORCID 0000-0001-7499-4966
Jessica FeltonDepartment of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Dana RoqueDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD, USA.
Gautam RaoDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD, USA.
Andrea G ShipperHealth Sciences & Human Services Library, University of Maryland School of Medicine, Baltimore, MD, USA.
Tatiana V D SansesDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Maryland's Organized Research Effort in Women's Health (MORE-WH)K12HD043489 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI TRACY, J. KATHLEEN · 2002 to 2016
$7.0M
Urinary Incontinence, Mobility, Muscle Function in Older WomenR03AG053281 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI SANSES, TATIANA V.D. · 2016 to 2017
$231k
NIA NIH HHS R03 AG053281NICHD NIH HHS K12 HD043489
6 · The paper itself

Abstract

introduction and hypothesisPelvic floor disorders (PFDs) negatively affect quality of life in the general population, and their prevalence in gynecologic cancer survivors has not been systematically described. This study aimed to determine the prevalence of PFDs in cancer survivors. We hypothesized that the prevalence of PFDs in the gynecologic cancer population would be higher than in the general female population.

methodsWe searched PubMed (1809 to present), EMBASE (1974 to present), and the Cochrane Central Register of Controlled Trials (CENTRAL) through May 2017. The search combined subject headings, title, and abstract words for gynecologic cancer, PFDs, and prevalence. Any studies evaluating the prevalence of PFDs in gynecologic malignancies were included.

resultsA total of 550 articles met the designated search criteria and 31 articles were included in this review. In cervical cancer survivors, before treatment the prevalences of stress urinary incontinence (SUI), urgency urinary incontinence (UUI) and fecal incontinence (FI) were 24-29%, 8-18% and 6%, respectively, and after treatment the prevalences of SUI, UUI, urinary retention, FI, fecal urge, dyspareunia and vaginal dryness were 4-76%, 4-59%, 0.4-39%, 2-34%, 3-49%, 12-58% and 15-47%, respectively. In uterine cancer survivors, before treatment the prevalences of SUI, UUI and FI were 29-36%, 15-25% and 3%, respectively, and after treatment the prevalences of urinary incontinence (UI) and dyspareunia were 2-44% and 7-39%, respectively. In vulvar cancer survivors, after treatment the prevalences of UI, SUI and FI were 4-32%, 6-20% and 1-20%, respectively. In ovarian cancer survivors, the prevalences of SUI, UUI, prolapse and sexual dysfunction were 32-42%, 15-39%, 17% and 62-75%, respectively.

conclusionsPFDs are prevalent in gynecologic cancer survivors and this is an important area of clinical concern and future research.

Indexed as

Cancer SurvivorsFemaleGenital Neoplasms, FemaleHumansPelvic Floor DisordersPrevalenceGynecologic cancerPelvic floor disordersPrevalenceSurvivor

Identifiers

PMID28929201
PMCPMC7329191
OpenAlexW2755564214

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.